Cite
MLA Citation
Xue Yan Jiang et al.. “Radium-223 therapy in symptomatic metastatic castrate resistant prostate cancer (mCRPC) – sequential use post-abiraterone/prednisolone.” Clinical oncology, vol. 31, n.d., pp. e10–e11. http://access.bl.uk/ark:/81055/vdc_100092811078.0x00002d